🇺🇸 FDA
Pipeline program

[18F]PI-2620

Phase 2 small_molecule active

Quick answer

[18F]PI-2620 for Progressive supranuclear palsy, Parkinson's disease is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Institut für biomedizinische Analytik NMR-Imaging GmbH
Indication
Progressive supranuclear palsy, Parkinson's disease
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials